Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022
16 mars 2022 16h15 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights
15 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational product candidate, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical...
Acumen Pharmaceuticals to Present at Upcoming Investor Conferences
08 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel...
Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
02 nov. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first...
Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease
07 oct. 2021 08h00 HE
|
Acumen Pharmaceuticals, Inc.
ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Enrollment of early Alzheimer’s...
Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights
16 août 2021 16h05 HE
|
Acumen Pharmaceuticals, Inc.
Acumen’s investigational drug, ACU193, is the first humanized monoclonal antibody discovered and developed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical trialsInitiated...
Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering
30 juin 2021 22h44 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a...